

ARTICLE

Open Access

α -catenin SUMOylation increases I κ B α stability and inhibits breast cancer progression

Huan Chen¹, Zhaowei Xu¹, Xiahui Li¹, Yangyang Yang¹, Bowen Li¹, Yanan Li¹, Kangkai Xia¹, Jian Wang², Shujing Li¹, Miao Wang¹ and Huijian Wu^{1,2}

Abstracts

α -catenin has been demonstrated to suppress several different types of cancers. Here we demonstrate that α -catenin is modified by SUMO protein, which covalently binds α -catenin at the carboxy terminus at lysine 870. Substitution of lysine 870 with arginine completely abolishes α -catenin SUMOylation. This modification can be removed by SENP1. However, α -catenin SUMOylation does not affect its stability and subcellular localization. In addition, we observed that the SUMOylation-deficient α -catenin mutant has a reduced interaction with I κ B α which prevents subsequent ubiquitination of I κ B α , and therefore a reduced suppression of expression of the NF- κ B target genes *TNF- α* , *IL-8*, *VEGF*, and *uPA*. In addition, the α -catenin SUMOylation mutant shows impaired suppression of tumor growth. These results demonstrate that SUMOylation at lysine 870 of α -catenin plays a key role in the suppression of the NF- κ B pathway, which inhibits breast cancer tumor growth and migration.

Introduction

The tumor-suppressor gene *CTNNA1* (encoding α -catenin) is one of the most frequently deleted^{1,2} or mutated³ genes in cancer. α -catenin is an essential protein in adherens junctions, which are critical for maintaining intercellular adhesion and cellular polarity^{4,5}. The tumor-suppressor activities of α -catenin involve following signaling pathways. An siRNA screen suggested that the YAP1 may be a downstream effector of α -catenin⁶, which inhibits the transcriptional activity of YAP1 by promoting its cytoplasmic sequestration⁷. α -catenin is frequently downregulated in human skin cancer⁸, and an α -catenin-knockout skin squamous cell carcinoma mouse model showed upregulation of many NF- κ B downstream genes⁹. α -catenin suppresses p50/p65 nuclear localization by

binding to I κ B α and increasing its protein stability in breast cancer¹⁰. Moreover, α -catenin directly interacts and promotes β -catenin degradation¹¹.

SUMOylation is a post-translational modification where SUMO covalently binds to target proteins¹². SUMOylation regulates numerous cellular stress responses including DNA repair, transcriptional regulation, and RNA metabolism^{12,13}. Like with ubiquitination, SUMOylation involves several steps and three classes of enzymes including E1 enzyme SAE1/SAE2, only E2 enzyme Ubc9 and diverse E3 enzymes which accelerate the SUMOylation rate of final step¹⁴. SUMOylation is a dynamic process which regulates substrate functions including subcellular distribution, protein stability and control of protein interactions^{15,16}. Numerous studies indicate that NF- κ B pathway, such as stabilizing I κ B α ¹⁷, activation of the I κ B kinase NEMO¹⁸, and promoting p50 maturation¹⁹, is regulated by SUMOylation. Given that α -catenin can interact with Ubc9²⁰ indicates that α -catenin is a target of SUMO. A computer analysis of the α -catenin protein sequence reveals two conserved SUMOylation

Correspondence: Miao Wang (wangm@dlut.edu.cn) or Huijian Wu (wuhj@dlut.edu.cn)

¹School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China

²School of Life Science and Medicine, Dalian University of Technology, Panjin, China

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.




Fig. 1 α -catenin is Modified by SUMO. **a** HEK293T cells were co-transfected with relevant plasmids, cells were collected at 48 h after transfection and immunoprecipitated with anti-Flag gel (Bimake, South Loop West, Suite 175, Houston, B23101). ** non-specific bands. **b** HEK293T cells co-transfected with GFP-SUMO1 or its SUMOylation mutant and Flag- α -catenin. Cell extracts were immunoprecipitated with Flag gel described in **a**. **c** HEK293T cells were transfected with indicated plasmids and treated with the same protocol in **a**. **d** HEK293T cells were transfected relevant plasmids and the cell lysates were immunoprecipitated with Myc-tag antibody. **e** Endogenous α -catenin-SUMO1 were purified with denaturing condition as described in methods. **f** HEK293T cell lysates were immunoprecipitated with anti- α -catenin antibody or control IgG followed by western blot with anti-Ubc9 antibody

sites: lysine 86 and 870. In this article, we demonstrate that α -catenin is SUMOylated at lysine 870 in vivo. Mutating K870 to arginine reduces the binding of α -catenin to I κ B α and negatively regulates NF- κ B target gene expression, therefore inhibiting α -catenin tumor-suppressor activity in breast cancer. Collectively, our findings suggest that α -catenin SUMOylation is of great importance in regulating α -catenin tumor-suppressor activity.

Results


α -catenin is modified by SUMO

To determine whether α -catenin is modified by SUMO, Exogenous α -catenin SUMOylation were detected in HEK293T cells co-transfected with Flag-labeled α -catenin together with Myc-labeled SUMO1, SUMO2, SUMO3 or empty vector. Flag-tagged proteins were purified in NEM-TNE lysis buffer using Flag gel. We observed Flag- α -catenin-SUMO bands only when cells were co-transfected with three types of SUMO protein (Fig. 1a), indicating that α -catenin is substrate of SUMO protein. Since SUMO1 modifies target proteins via its glycine 97, and mutating G97 to arginine is enough to destroy modification function²¹. To further confirm this, HEK293T cells were transfected with Flag- α -catenin together with WT

SUMO1 or its mutant SUMO1-G97A and analyzed the SUMOylated proteins. We observed α -catenin was only modified by WT SUMO1 but not SUMO-G97A (Fig. 1b). In addition, the abundance of SUMOylation can be significantly enhanced by Ubc9, a SUMO E2 conjugating enzyme²². Cells co-transfected with Ubc9 and SUMO1 showed significantly higher amounts of the α -catenin-SUMO1 band (Fig. 1c). Moreover, we observed that SUMO1 could be removed from α -catenin by WT SENP1 instead of catalytic mutant SENP1 (SENP1m) (Fig. 1d). We next performed SUMOylation assays in HEK293T cells to detect endogenous α -catenin-SUMO1 in vivo, α -catenin was immunoprecipitated with α -catenin antibody and we subsequently observed SUMOylated α -catenin (Fig. 1e). In addition, endogenous α -catenin co-immunoprecipitated with Ubc9 (Fig. 1f). Together, α -catenin is modified by SUMO protein.

SUMO modification of α -catenin at lysine 870

A computer analysis of the α -catenin protein sequence revealed two classical SUMOylation consensus motifs including lysine 86 and 870. In addition, two potential SUMOylation motif are conserved in diverse species (homo sapiens, mouse, zebrafish, xenopus) (Fig. 2a). We constructed single point mutations in the putative lysine




residues of α -catenin and analyzed SUMO conjugation. SUMOylated α -catenin band was totally lost when cells were co-transfected with α -catenin K870R (Fig. 2b). Similarly, SUMO2 and SUMO3 conjugation to α -catenin was nearly dissolved with the K870R α -catenin mutation (Fig. 2c). These results point to the lysine residue at position 870 as a SUMO-acceptor site in α -catenin. To verify this information, Ubc9 was used to enhance the SUMOylation level of WT α -catenin and the K870R α -catenin mutant. As expected, α -catenin SUMOylation was completely abolished in the K870R α -catenin mutant, even when cells were co-transfected with Ubc9 (Fig. 2d). In mammals, there are three α -catenin proteins including α E-catenin, α N-catenin and α T-catenin, which are encoded by *CTNNA1*, *CTNNA2* and *CTNNA3*, respectively²³. Surprisingly, we also observed similar SUMOylation sites in α N-catenin and α T-catenin (Fig. 2e). These data indicate that lysine residues at position 870 of α -catenin is implicated in the conjugating to SUMO.

SUMOylation does not affect stability of α -catenin and cellular localization

Since SUMOylation usually regulates substrate subcellular distribution, we wondered whether α -catenin SUMOylation is required for localizations to adherens junctions by transfecting WT Flag- α -catenin or the

K870R mutant into MDA-MB-231 cells and monitoring α -catenin subcellular localization using immunofluorescent staining. The results showed that α -catenin mainly aggregated in the cytoplasm, regardless of mutation status (Fig. 3a). To confirm this phenomenon, we therefore detected the subcellular distribution of WT α -catenin or its SUMOylation mutant and observed the similar results when using a cell fractionation assay (Fig. 3b and Supplementary Figure 1). We then analyzed the subcellular distribution of α -catenin-SUMO. HEK293T cells were transfected with WT Flag- α -catenin or with K870R mutant Flag- α -catenin together with or without of Ubc9 and SUMO1 and analyzed α -catenin-SUMO localization. As expected, SUMOylation did not affect α -catenin nucleus and cytoplasm distribution (Fig. 3c). However, expected α -catenin-SUMO1 band was mainly evident in the cytoplasm (Fig. 3c), indicating that α -catenin-SUMO1 is distributed in the cytoplasm. Since SUMOylation usually affects target protein degradation rates, we therefore detected the protein stability of WT α -catenin and its SUMOylation mutant K870R. We observed that both WT α -catenin and the K870R α -catenin mutant were degraded at a similar rate (Fig. 3d). Together, SUMOylation does not affect α -catenin subcellular distribution and protein stability.




α -catenin SUMOylation inhibits NF- κ B pathway

α -catenin is a tumor suppressor involved in Wnt^{11,24}, Hippo-Yap^{6,7} and NF- κ B signaling^{9,10} pathways. To determine whether SUMOylation of α -catenin regulates these pathways, we performed TOPFlash, Tead4 luciferase, and pNF- κ B-luciferase assays in HEK293T cells, respectively. Unexpectedly, the K870R α -catenin mutant showed significantly reduced inhibition of the pNF- κ B-luciferase with or without TNF- α stimulation, whereas the α -catenin SUMOylation mutant did not affect TOPFlash and Tead4 luciferase activity compared to WT α -catenin (Fig. 4a). Since α -catenin inhibits NF- κ B signaling by stabilizing I κ B α in basal-like breast cancer¹⁰, we attempted to explore whether I κ B α protein abundance is affected by α -catenin SUMOylation. For this hypothesis, we generated MDA-MB-231 and MDA-MB-157 cells that stably express WT α -catenin or the K870R α -catenin mutant using lentivirus. MDA-MB-157 cells carry a biallelic inactivating mutation in α -catenin and have therefore lost α -catenin expression¹. α -catenin expression was comparable between the α -catenin mutant and WT when assessed using western blotting (Fig. 4b), indicating that the α -catenin K870R mutant does not affect α -catenin transcription or protein stability. In addition, the α -catenin K870R mutant had little effect on I κ B α protein level compared to WT α -catenin (Fig. 4b). To further evaluate the effects of α -catenin SUMOylation at K870 on the

transcriptional output of the NF- κ B pathway, we measured the mRNA expression of NF- κ B target genes *TNF- α* , *IL-8*, *VEGF*, and *uPA*²⁵⁻²⁷ in WT α -catenin or K870R α -catenin mutant-expressing MDA-MB-157 cells. As expected, upregulation of WT α -catenin significantly suppressed these NF- κ B target genes. In contrast, the SUMOylation-deficient K870R α -catenin mutant was unable to inhibit expression of these genes in MDA-MB-157 cells. (Fig. 4c). Moreover, α -catenin SUMOylation mutant did not affect its inhibitory effect of Hippo-Yap target genes *CTGF* and *CRY61* in MDA-MB-157 cells (Supplementary Figure. 2a). Surprisingly, no matter WT α -catenin or α -catenin SUMOylation mutant did not inhibit Wnt target genes *CCND1* and *C-MYC* in MDA-MB-157 cells (Supplementary Figure. 2b). Taken together, NF- κ B pathway is regulated by α -catenin SUMOylation.

SUMOylation enhances the interaction between α -catenin and I κ B α

Since α -catenin SUMOylation deficiency attenuates its suppressive effect on the NF- κ B pathway in MDA-MB-231 and MDA-MB-157 cells, we speculated that endogenous α -catenin was SUMOylated in these two cell lines. As expected, we found that endogenous α -catenin was modified by SUMO1 in MDA-MB-231 cells instead of MCF-7 and T47D cells (Fig. 5a), and the α -catenin-SUMO1 band was also present in lysates from MDA-MB-



157 cells when cells were infected with WT α-catenin but not the K870R mutant (Fig. 5b), suggesting that endogenous α-catenin may mainly be SUMOylated in basal-like breast cancer cells. Since loss of α-catenin did not affect NF-κB pathway in the luminal subtype¹⁰, knockout of α-catenin in MCF-7 cells did not decrease protein level of IκBα (Fig. 5c). Moreover, the SUMOylation level of α-catenin was unaffected by TNF-α stimulation (Fig. 5d). Similar results were also observed when exogenous α-catenin SUMOylation assay was used in HEK293T cells (Supplementary Figure 3). Since substrate protein interactions usually affected by SUMOylation²⁸. We therefore examined whether SUMOylation of α-catenin affects its ability to bind IκBα. Overexpression of WT α-catenin significantly increased the amount of IκBα co-immunoprecipitated. In contrast, overexpression of the K870R α-catenin mutant had no obvious effect on its interaction with IκBα in MDA-MB-231 cells (Fig. 5e). To further confirm that α-catenin SUMOylation increases its interaction with IκBα, an α-catenin-null MDA-MB-157 cell line was used. As expected, the amount of IκBα immunoprecipitated with WT α-catenin was much higher

than with the K870R α-catenin mutant (Fig. 5f). To further confirm this, we examined IκBα ubiquitination. Overexpression of WT α-catenin significantly decreased the IκBα ubiquitination. However, K870R α-catenin mutant markedly lost this function (Fig. 5g). These results indicate that α-catenin SUMOylation increases its binding to IκBα.

SUMOylation-deficient α-catenin attenuates its tumor-suppressor activity

α-catenin has been shown to suppress the NF-κB pathway to inhibit cell proliferation and migration^{9,10}. We explored whether α-catenin SUMOylation is responsible for tumor-suppressor function. In agreement with our hypothesis, WT α-catenin significantly inhibited cell proliferation (Fig. 6a and Supplementary Figure 4) and migration (Fig. 6b), whereas the K870R α-catenin mutants significantly lost the ability to suppress growth and migration. We then generated 4T1 cells to stably express the control empty vector, WT α-catenin or the K870R α-catenin mutant, and we analyzed NF-κB target genes TNF-α and uPA protein level. 4T1 cells is a





Fig. 5 SUMOylation enhances α -catenin interacting with I κ B α . **a** MCF-7, T47D, and MDA-MB-231 cell lysates were immunoprecipitated with anti- α -catenin antibody or control IgG followed by Western blot with anti-SUMO1 antibody. **b** MDA-MB-157 cells transfected with wild-type α -catenin or its mutant K870R and then subjected to immunoprecipitation with anti- α -catenin antibody followed by Western blot with anti SUMO1 antibody. **c** MCF-7 and MDA-MB-231 cells were transfected with α -catenin-shRNA or its control vector followed by Western blot with anti- α -catenin or anti-I κ B α antibody, respectively. **d** MDA-MB-231 cells treated with or without 10 ng ml⁻¹ TNF- α 15 min before lysis, and then lysates were immunoprecipitated with anti- α -catenin antibody or control IgG followed by Western blot with anti-SUMO1 antibody. **e** MDA-MB-231 cells transfected with wild-type α -catenin or its mutant K870R and then subjected to immunoprecipitation with anti- α -catenin antibody followed by Western blot with anti-I κ B- α antibody. **f** In the same condition as **e**. **g** HEK293T cells were transfected with indicated plasmids. Cells were treated with 10 μ M MG132 and 20 ng ml⁻¹ of TNF- α for 30 min, and I κ B- α was purified with anti-Flag gel followed by Western blot with HA or anti-Flag antibody. “*” non-specific bands

rapidly growing and highly metastatic murine basal-like breast cancer cell line, in which the NF- κ B signaling pathway is hyperactivated²⁹. Like what we observed above, WT α -catenin significantly suppressed the protein level of TNF- α and uPA and inhibited colony formation. In contrast, K870R mutant lost these effects (Fig. 6c, d). We next subcutaneously transplanted stably transfected 4T1 cells expressing either α -catenin or K870R mutant in BABL/c mice. Both the WT and K870R mutant dramatically inhibited the subcutaneous growth of 4T1 cells. However, the tumor volumes and weights in the group with expression of the K870R α -catenin mutant were much greater than the group with expression of WT α -catenin (Fig. 6e–g). In addition, WT α -catenin 4T1 tumors exhibited downregulation of TNF- α , uPA and proliferation marker Ki-67. In contrast, the K870R α -catenin mutant significantly lost these abilities (Fig. 6h).

Taken together, SUMOylation-deficient α -catenin has lost tumor-suppressor activity in vivo.

Discussion

α -catenin is an important component of adherens junctions, which bind to actin filaments to maintain cellular connection integrity between neighboring cells^{4,30}. Three α -catenin isoforms have been identified, including α E-catenin, α N-catenin and α T-catenin. α E-catenin is mainly expressed in epithelial tissues³¹ and is critical for the development of these tissues. For example, α -catenin-knockout nude mice display impaired hair growth and exhibit tumor-like nodules in skin tissues⁹. Accumulating evidence has revealed that downregulation or a loss of α -catenin expression contributes to multiple types of cancer, such as leukemia², human skin squamous cell carcinoma^{6–8}, colorectal^{11,24,32–34}, breast¹⁰ and prostate



cancer³⁵. These studies and clinical correlation analyses have demonstrated that α -catenin inhibits cancer progression in different tissues via suppressing Wnt, Hippo-YAP, and NF- κ B pathways, indicating that the function of α -catenin is affected by the surrounding environment. Numerous prior studies have focused on α -catenin biological function by manipulating protein levels using knockout or knock-in methods. However, the post-translational modifications of α -catenin need to be further elucidated. For example, a recent study has revealed that α -catenin is phosphorylated by casein kinase 1 and 2, which promotes intercellular adhesion³⁶. Our data supports that a different kind of reversible post-translational modification may regulate α -catenin's role in the NF- κ B pathway. The SUMOylation site at lysine 870 that we identified in α -catenin is highly conserved, such as in the

mouse, xenopus and zebrafish. We also find a similar SUMOylation site in α N-catenin and α T-catenin, indicating that these two isoforms may be SUMOylated in vivo.

Since no suitable therapy and drugs for triple-negative breast cancer cells (TNBC), it has a lower five-year life rate than other subtypes³⁷. Emerging studies have identified that aberrant regulation of the SUMOylation pathway affects the progression of breast cancer. BRCA1 mutation status correlates with high Ubc9 expression which results in increased proliferation and migration of triple-negative breast cancer³⁸. SUMOylation pathway also contributes to promoting the transition of breast cancer cells from a luminal to basal phenotype and is required to maintain cancer stem cell properties^{39,40}. These studies may explain why endogenous α -catenin was

not SUMOylated in MCF-7 and T47D (Fig. 5a). Activation of NF- κ B, which is best known to be regulated by ubiquitination⁴¹, is tightly correlated with various kinds of tumors^{29,42}. Degradation of I κ B α is a key step for NF- κ B activation, which subsequently activates downstream proinflammatory genes which initiate tumor cells proliferation and migration⁴³. Like ubiquitination, NF- κ B is also regulated by SUMOylation pathway⁴⁴. For example, I κ B α is modified by SUMO1, which prevents its ubiquitination by competing with Ubiquitin for the same lysine at position 21¹⁷. As it has been well-demonstrated that the SIM (SUMO-interacting motif) is important for mediating protein-protein interactions^{45,46}, we speculate that I κ B α contains a SIM motif which promotes the interaction between I κ B α and SUMOylated α -catenin.

In this research, we demonstrate that α -catenin is SUMOylated at lysine 870, enhancing its interaction with I κ B α , and therefore leading to upregulation of I κ B α protein levels and inactivation of NF- κ B pathway. We also demonstrate that α -catenin SUMOylation does not affect protein stability (Fig. 3d) and subcellular localization (Fig. 3a,b), which may explain why TOPFlash and Tead4 luciferase activities were unaffected by α -catenin SUMOylation (Fig. 4a). Furthermore, we demonstrate that α -catenin SUMOylation does not require TNF- α stimulation (Fig. 5d). These data provide a molecular mechanism for α -catenin SUMOylation and reveal an alternative to the canonical NF- κ B signaling pathway that connects an important post-translational modification of α -catenin with the NF- κ B signaling pathway. Collectively, our data has revealed that SUMO modification of α -catenin promotes its interaction with I κ B α and allows for tumor suppressive activity.

Materials and methods

Plasmids and antibodies

Myc-labeled SUMO1, SUMO2, SUMO3, Flag-SENP1, Flag-SENP1m, GFP-SUMO1, and GFP-SUMO1-G97A were previously described^{32,47,48}. Tead4 luciferase construct was a kind gift from Dr. Ximei Wu⁴⁹. The following plasmids were a kind gift provided by Dr. Hai-long Piao: SFB- α -catenin construct, SFB I κ B α construct, Myc- α -catenin construct, pLOC α -catenin construct, Myc-I κ B α construct, HA-Ub (ubiquitin) construct, pNF- κ B luciferase reporter construct, TOPFlash luciferase reporter construct, pGPIZ *CTNNA1* shRNA construct¹⁰. GFP- α -catenin was amplified from SFB α -catenin construct. GFP- α -catenin sense primer: 5'-CGGAATC-CACTGCTGTCCATGCA-3'. GFP- α -catenin reverse primer: 5'-GGGGTACCCCTTAGATGCTGTCCA-TAGCTT-3' pLOC α -catenin mutant (K870R), GFP α -catenin mutant (K870R) and Flag- α -catenin mutants (K87R, K870R) were generated using a site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).

The following antibodies were used: Flag, GFP, HA, Myc, α -catenin rabbit polyclonal antibodies and Flag, GAPDH mouse monoclonal antibodies (Sigma, Saint Louis, MO, USA), rabbit anti-I κ B α antibody (CST, 3 Trask Lane Danvers, MA, USA), rabbit SUMO1 polyclonal antibody (Abcam, Cambridge, MA, USA), SUMO1, Fibrillarin mouse monoclonal antibodies and rabbit anti-UBC9 (Santa Cruz Biotechnology, Dallas, Texas, USA), mouse anti-TNF- α , rabbit anti-uPA, rabbit anti-Ki-67 antibodies (Proteintech, Manchester, M3 3WF, UK), mouse anti- β -tubulin antibody (ZSGB-BIO, Beijing, China).

Cell culture and transfection

MD-MBA-157 cells were purchased from China Infrastructure of Cell Line Resource and cultured under conditions specified by the provider. HEK293T, MCF-7, T47D, MD-MBA-231, and 4T1 cells were previously described⁵⁰. Transfection assay was performed with Lipofectamine 2000 (Invitrogen, Auckland, New Zealand).

Lentiviral transduction

Lentivirus containing medium was generated using three plasmids lentivirus package system. Cells were incubated with virus and selected using suitable antibiotic.

Transwell assay

Transwell assay was previously described⁵¹. MDA-MB-231 cells (2×10^4) or MDA-MB-157 cells (5×10^4) were infected with virus and selected by blasticidin before plated.

Luciferase reporter assay

Cells were plated into a 24-well plate at a confluency of 30%, and transfected with relevant plasmids 24 h later. The luciferase activity was tested as previously described⁵¹.

Western blot, Co-immunoprecipitation, Immunohistochemistry

Cells extracts were generated using TNE lysis buffer. Western blot and Co-immunoprecipitation were previously described³². TNE lysis buffer (20 mM Tris-HCl [pH = 6.8], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 10% Glycerol and complete protease inhibitor) containing 20 mM N-Ethylmaleimide (NEM, pierce) for exogenous SUMOylation assay. The method for analysis of endogenous α -catenin-SUMO1 was previously described¹⁷. Immunohistochemistry (IHC) were performed as previously described⁵¹.

Cytoplasm and nucleus separation

Cytoplasm and nucleus separation assay was performed using Protein Extraction Kit (Wanleibio).

Immunofluorescence staining

MDA-MB-231 cells were transfected with Flag- α -catenin or its SUMOylation mutant K870R using Lipofectamine 2000. Transfected cells were seeded at coverslip 48 h later. Immunofluorescence staining was described in our previously studies^{32,51}.

Cell growth assay

For crystal violet staining assay, cells were infected with virus containing medium, and then plated in 35 mm dish. After clones were clearly visible, cells were stained with crystal violet. MTT assay was described in our previous study³².

Quantitative RT-PCR assays

Total RNA was extracted using RNAiso reagent (Takara Biotechnology, Dalian, China). cDNA was generated using a Reverse Transcription System (Takara). Normalized abundance of mRNA were measured using SYBR premix Ex Taq (Takara). The primers were designed as follows: TNF- α sense primer: cccaggcagtcagatcatcttc. TNF- α reverse primer: agctgccctcagcttga. IL-8 sense primer: 5'-tttgccaaggagtgctaaga IL-8 reverse primer: aacctctgcaccagtttc. VEGFA sense primer: cggaaccagatctctcacc. VEGFA reverse primer aaaatggcgaatccaattcc. uPA sense primer: agtgtcagcagccact. uPA reverse primer cccctgagtcctctgg. CCND1 sense primer: gctgctcctggtgaacaagc. CCND1 reverse primer aagtgttcaatgaaatcgtg. C-MYC sense primer: cagctggagatgatgaccga. C-MYC reverse primer ttgatgaaggctcgtcgtc. CTGF sense primer: gccagaccaactatgattag. CTGF reverse primer: tctcgtatcttctctgtagt. CRY61 sense primer: gactgtgaagatgcggtcc. CRY61 reverse primer ctgtagaagggaaacgtgc.

Mice with homografts expressing WT α -catenin and K870R α -catenin

BALB/c mice (8 weeks old) were purchased from the Laboratory Animal Center of Dalian Medical University. Mice were managed and raised according to the procedures of the Ethics Committee for Biology and Medical Science of Dalian University of Technology. BALB/c mice were implanted subcutaneously with 4T1 cells infected with relevant virus. Tumor size and volume were recorded once a week. Tumor volume calculating method was used according to a previous study¹⁰.

Statistical analysis

Data were showed as means \pm SDs. An unpaired *t*-test was used when the results from two groups were compared. Experimental data is considered to be significant when $p < 0.5$. * $p < 0.05$, ** $p < 0.01$.

Acknowledgements

We thank Dr. Hai-long Piao, Dalian Institute of Chemical Physics, Chinese Academy of Sciences in China, for his constructs. This research was supported by grants (81672792 to H.W) from National Natural Science Foundation of China

Author details

¹School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China. ²School of Life Science and Medicine, Dalian University of Technology, Panjin, China

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (<https://doi.org/10.1038/s41389-018-0037-7>).

Received: 8 November 2017 Revised: 5 January 2018 Accepted: 29 January 2018

Published online: 13 March 2018

References

- Hollestelle, A. et al. Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations. *Breast Cancer Res. Treat.* **122**, 125–133 (2010).
- Liu, T. X. et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. *Nat. Med.* **13**, 78–83 (2007).
- Chen, X. X. et al. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia. *Leuk. Res.* **38**, 613–618 (2014).
- Buckley, C. D. et al. Cell adhesion. The minimal cadherin-catenin complex binds to actin filaments under force. *Science* **346**, 1254211 (2014).
- Harris, T. J. & Tepass, U. Adherens junctions: from molecules to morphogenesis. *Nat. Rev. Mol. Cell Biol.* **11**, 502–514 (2010).
- Silvis, M. R. et al. Alpha-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. *Sci. Signal.* **4**, ra33 (2011).
- Schlegelmilch, K. et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. *Cell* **144**, 782–795 (2011).
- Li, P. et al. AlphaE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. *Genes Dev.* **30**, 798–811 (2016).
- Kobiela, A. & Fuchs, E. Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. *Proc. Natl Acad. Sci. USA* **103**, 2322–2327 (2006).
- Piao, H. L. et al. Alpha-catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-kappaB signalling. *Nat. Cell Biol.* **16**, 245–254 (2014).
- Choi, S. H., Estaras, C., Moresco, J. J., Yates, J. R. 3rd & Jones, K. A. alpha-Catenin interacts with APC to regulate beta-catenin proteolysis and transcriptional repression of Wnt target genes. *Genes Dev.* **27**, 2473–2488 (2013).
- Hay, R. T. SUMO: a history of modification. *Mol. Cell* **18**, 1–12 (2005).
- Johnson, E. S. Protein modification by SUMO. *Annu. Rev. Biochem.* **73**, 355–382 (2004).
- Geiss-Friedlander, R. & Melchior, F. Concepts in sumoylation: a decade on. *Nat. Rev. Mol. Cell Biol.* **8**, 947–956 (2007).
- Qi, Q., Liu, X., Brat, D. J. & Ye, K. Merlin sumoylation is required for its tumor suppressor activity. *Oncogene* **33**, 4893–4903 (2014).
- Wang, Y. & Dasso, M. SUMOylation and deSUMOylation at a glance. *J. Cell Sci.* **122**(Pt 23), 4249–4252 (2009).
- Desterro, J. M., Rodriguez, M. S. & Hay, R. T. SUMO-1 modification of Ikkappa-Balpha inhibits NF-kappaB activation. *Mol. Cell* **2**, 233–239 (1998).

18. Huang, T. T., Wuerzberger-Davis, S. M., Wu, Z. H. & Miyamoto, S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. *Cell* **115**, 565–576 (2003).
19. Vatsyayan, J., Qing, G., Xiao, G. & Hu, J. SUMO1 modification of NF-kappaB2/p100 is essential for stimuli-induced p100 phosphorylation and processing. *EMBO Rep.* **9**, 885–890 (2008).
20. Kotlyar, M., Pastrello, C., Sheahan, N. & Jurisica, I. Integrated interactions database: tissue-specific view of the human and model organism interactomes. *Nucleic Acids Res.* **44**(D1), D536–D541 (2016).
21. Kamitani, T., Nguyen, H. P. & Yeh, E. T. Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. *J. Biol. Chem.* **272**, 14001–14004 (1997).
22. Gong, L., Kamitani, T., Fujise, K., Caskey, L. S. & Yeh, E. T. Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. *J. Biol. Chem.* **272**, 28198–28201 (1997).
23. Kobiela, A. & Fuchs, E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. *Nat. Rev. Mol. Cell Biol.* **5**, 614–625 (2004).
24. Giannini, A. L., Vivanco, M. & Kypta, R. M. alpha-catenin inhibits beta-catenin signaling by preventing formation of a beta-catenin* T-cell factor* DNA complex. *J. Biol. Chem.* **275**, 21883–21888 (2000).
25. Collart, M. A., Baeuerle, P. & Vassalli, P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. *Mol. Cell Biol.* **10**, 1498–1506 (1990).
26. Kong, D., Li, Y., Wang, Z., Banerjee, S. & Sarkar, F. H. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. *Cancer Res.* **67**, 3310–3319 (2007).
27. Kunsch, C. & Rosen, C. A. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. *Mol. Cell Biol.* **13**, 6137–6146 (1993).
28. Shitashige, M. et al. Regulation of Wnt signaling by the nuclear pore complex. *Gastroenterology* **134**, 1961–1971 (2008). 71 e1-4.
29. Jin, W. J. et al. NF-kappaB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells. *Exp. Mol. Med.* **49**, e295 (2017).
30. Takeichi, M. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. *Nat. Rev. Mol. Cell Biol.* **15**, 397–410 (2014).
31. Nagafuchi, A., Takeichi, M. & Tsukita, S. The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. *Cell* **65**, 849–857 (1991).
32. Ao, X. et al. Sumoylation of TCF21 downregulates the transcriptional activity of estrogen receptor-alpha. *Oncotarget* **7**, 26220–26234 (2016).
33. Raftopoulos, I., Davaris, P., Karatzas, G., Karayannacos, P. & Kouraklis, G. Level of alpha-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential, and survival. *J. Surg. Oncol.* **68**, 92–99 (1998).
34. Ropponen, K. M., Eskelinen, M. J., Lipponen, P. K., Alhava, E. M. & Kosma, V. M. Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. *J. Clin. Pathol.* **52**, 10–16 (1999).
35. Inge, L. J. et al. Alpha-catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. *Mol. Cancer Ther.* **7**, 1386–1397 (2008).
36. Escobar, D. J. et al. alpha-Catenin phosphorylation promotes intercellular adhesion through a dual-kinase mechanism. *J. Cell Sci.* **128**, 1150–1165 (2015).
37. Anders, C. & Carey, L. A. Understanding and treating triple-negative breast cancer. *Oncology (Williston Park)* **22**, 1233–1239 (2008). discussion 39–40, 43.
38. Xu, J. et al. BRCA1 mutation leads to deregulated Ubc9 levels which triggers proliferation and migration of patient-derived high grade serous ovarian cancer and triple negative breast cancer cells. *Int. J. Chronic Dis. Ther.* **2**, 31–38 (2016).
39. Bogachek, M. V. et al. Sumoylation pathway is required to maintain the basal breast cancer subtype. *Cancer Cell.* **25**, 748–761 (2014).
40. Bogachek, M. V. et al. Inhibiting the SUMO pathway represses the cancer stem cell population in breast and colorectal carcinomas. *Stem Cell Rep.* **7**, 1140–1151 (2016).
41. Skaug, B., Jiang, X. & Chen, Z. J. The role of ubiquitin in NF-kappaB regulatory pathways. *Annu. Rev. Biochem.* **78**, 769–796 (2009).
42. Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. *Nat. Rev. Cancer* **2**, 301–310 (2002).
43. Jobin, C. & Sartor, R. B. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. *Am. J. Physiol. Cell Physiol.* **278**, C451–C462 (2000).
44. Lang, V. & Rodriguez, M. S. Innate link between NF-kappaB activity and ubiquitin-like modifiers. *Biochem. Soc. Trans.* **36**(Pt 5), 853–857 (2008).
45. Escobar-Cabrera, E. et al. Characterizing the N- and C-terminal Small ubiquitin-like modifier (SUMO)-interacting motifs of the scaffold protein DAXX. *J. Biol. Chem.* **286**, 19816–19829 (2011).
46. Song, J., Durrin, L. K., Wilkinson, T. A., Krontiris, T. G. & Chen, Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. *Proc. Natl Acad. Sci. USA* **101**, 14373–14378 (2004).
47. Bi, H. et al. SUMOylation of GPS2 protein regulates its transcription-suppressing function. *Mol. Biol. Cell* **25**, 2499–2508 (2014).
48. Hong, Y. et al. SUMOylation of DEC1 protein regulates its transcriptional activity and enhances its stability. *PLoS ONE* **6**, e23046 (2011).
49. Mei, L. et al. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions. *Cancer Lett.* **386**, 1–11 (2017).
50. Liu, Y. et al. FOXK2 transcription factor suppresses ERalpha-positive breast cancer cell growth through down-regulating the stability of ERalpha via mechanism involving BRCA1/BARD1. *Sci. Rep.* **5**, 8796 (2015).
51. Zhao, F. et al. DACH1 inhibits SNAIL-mediated epithelial-mesenchymal transition and represses breast carcinoma metastasis. *Oncogenesis* **4**, e143 (2015).
52. Li, S. et al. SUMOylation of PES1 upregulates its stability and function via inhibiting its ubiquitination. *Oncotarget* **7**, 50522–50534 (2016).